» Articles » PMID: 29030478

Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)

Overview
Journal Stroke
Date 2017 Oct 15
PMID 29030478
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Several studies suggested that statins during hospitalization were associated with better disability outcomes in patients with acute ischemic stroke, but only 1 small randomized trial is available.

Methods: We conducted a multicenter, open-label, randomized controlled trial in patients with acute ischemic strokes in 11 hospitals in Japan. Patients with acute ischemic stroke and dyslipidemia randomly received statins within 24 hours after admission in the early group or on the seventh day in the delayed group, in a 1:1 ratio. Statins were administered for 12 weeks. The primary outcome was patient disability assessed by modified Rankin Scale at 90 days.

Results: A total of 257 patients were randomized and analyzed (early 131, delayed 126). At 90 days, modified Rankin Scale score distribution did not differ between groups (=0.68), and the adjusted common odds ratio of the early statin group was 0.84 (95% confidence interval, 0.53-1.3; =0.46) compared with the delayed statin group. There were 3 deaths at 90 days (2 in the early group, 1 in the delayed group) because of malignancy. Ischemic stroke recurred in 9 patients (6.9%) in the early group and 5 patients (4.0%) in the delayed group. The safety profile was similar between groups.

Conclusions: Our randomized trial involving patients with acute ischemic stroke and dyslipidemia did not show any superiority of early statin therapy within 24 hours of admission compared with delayed statin therapy 7 days after admission to alleviate the degree of disability at 90 days after onset.

Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02549846.

Citing Articles

Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.

Katsiki N, Filippatos T, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A Atheroscler Plus. 2024; 55:74-92.

PMID: 38425675 PMC: 10901915. DOI: 10.1016/j.athplu.2024.01.004.


Statins affect human iPSC-derived cardiomyocytes by interfering with mitochondrial function and intracellular acidification.

Somers T, Siddiqi S, Maas R, Sluijter J, Buikema J, van den Broek P Basic Res Cardiol. 2024; 119(2):309-327.

PMID: 38305903 DOI: 10.1007/s00395-023-01025-x.


Statins and Cardiomyocyte Metabolism, Friend or Foe?.

Somers T, Siddiqi S, Morshuis W, Russel F, Schirris T J Cardiovasc Dev Dis. 2023; 10(10).

PMID: 37887864 PMC: 10607220. DOI: 10.3390/jcdd10100417.


Oatp (Organic Anion Transporting Polypeptide)-Mediated Transport: A Mechanism for Atorvastatin Neuroprotection in Stroke.

Williams E, Betterton R, Stanton J, Moreno-Rodriguez V, Lochhead J, Davis T Stroke. 2023; 54(11):2875-2885.

PMID: 37750296 PMC: 10615849. DOI: 10.1161/STROKEAHA.123.043649.


Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial....

Gao Y, Pan Y, Han S, Chen W, Jing J, Wang C Stroke Vasc Neurol. 2023; 8(3):249-258.

PMID: 36707080 PMC: 10359782. DOI: 10.1136/svn-2022-002084.